| Literature DB >> 28536889 |
Lisanne Vranken1,2, Caroline E Wyers3,4, Joop P W van den Bergh3,4,5, Piet P M M Geusens5,6.
Abstract
The aetiology of fractures in patients aged 50 years and older is multifactorial, and includes bone- and fall-related risks. The Fracture Liaison Service (FLS) is recommended to identify patients with a recent fracture and to evaluate their subsequent fracture risk, in order to take measures to decrease the risk of subsequent fractures in patients with a high risk phenotype. A literature survey was conducted to describe components of the bone- and fall-related phenotype of patients attending the FLS. Components of the patient phenotype at the FLS have been reported in 33 studies. Patient selection varied widely in terms of patient identification, selection, and FLS attendance. Consequently, there was a high variability in FLS patient characteristics, such as mean age (64-80 years), proportion of men (13-30%), and fracture locations (2-51% hip, <1-41% vertebral, and 49-95% non-hip, non-vertebral fractures). The studies also varied in the risk evaluation performed. When reported, there was a highly variability in the percentage of patients with osteoporosis (12-54%), prevalent vertebral fractures (20-57%), newly diagnosed contributors to secondary osteoporosis and metabolic bone disorders (3-70%), and fall-related risk factors (60-84%). In FLS literature, we found a high variability in patient selection and risk evaluation, resulting in a highly variable phenotype. In order to specify the bone- and fall related phenotypes at the FLS, systematic studies on the presence and combinations of these risks are needed.Entities:
Keywords: Fracture Liaison Service; Fractures; Phenotype; Secondary prevention
Mesh:
Year: 2017 PMID: 28536889 PMCID: PMC5544781 DOI: 10.1007/s00223-017-0284-1
Source DB: PubMed Journal: Calcif Tissue Int ISSN: 0171-967X Impact factor: 4.333
Patient selection procedure and number of identified patients, selected patients, attenders, and included attenders
| Author | Country | Year | Patient identification and selection for evaluation at the FLS | Selected patients, | Attenders, | Selection for publicationa | Subjects, | Subjects, %c | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| IP/OP | F/M | Age | Fracture | Additional criteria | ||||||||
| Patient selection for FLS evaluation conform recommendations, all FLS attenders selected for publication ( | ||||||||||||
| McLellan [ | GBR | 2003 | IP+OP | F+M | 50+ | All | 1 | 4671 | ||||
| Blonk [ | NLD | 2007 | IP+OP | F+M | 50+ | All | 1, 2, 5 | 1,220 | 1058 (87) | 1,058 (100) | 87 | |
| Eekman [ | NLD | 2014 | IP+OP | F+M | 50+ | All | 1, 9 | 2,207 | 1116 (51) | 1,116 (100) | 51 | |
| Fraser [ | AUS | 2016 | IP+OP | F+M | 50+ | All | 1 | 841 | 166 (20) | 166 (100) | 20 | |
| Malgo [ | NLD | 2016 | IP+OP | F+M | 50+ | All | 2, 3, 5, 6, 7 | 856 | 709 (83) | 709 (100) | 83 | |
| Naranjo [ | ESP | 2014 | IP+OP | F+M | 50+ | All | 1, 2, 6 | 532 | 330 (62) | 330 (100) | 62 | |
| Naranjo [ | ESP | 2015 | IP+OP | F+M | 50+ | All | 1, 2, 6 | 1324 | 759 (57) | 759 (100) | 57 | |
| Ojeda [ | ESP | 2010 | IP+OP | F+M | 50+ | All | 1, 2, 6 | 683 | 380 (56) | 380 (100) | 56 | |
| Woltman [ | NLD | 2010 | IP+OP | F+M | 50+ | All | 1,2 | 523 | 523 (100) | |||
| Ong [ | GBR | 2014 | IP+OP | F+M | 50+ | All | 1 | 4288 | 4,288 (100) | |||
| Van den Berg [ | NLD | 2014 | IP+OP | F+M | 50+ | All | 8 | 1898 | 1,898 (100) | |||
| Huntjens [ | NLD | 2011 | IP+OP | F+M | 50+ | All | 1, 2, 5 | 7199 | 7,199 (100) | |||
| Patient selection for FLS evaluation conform recommendations, subgroup of FLS attenders selected for publication ( | ||||||||||||
| Bours [ | NLD | 2011 | IP+OP | F+M | 50+ | All | 1, 2, 3 | 893 | 656 (73) | a | 626 (95) | 70 |
| De Klerk [ | NLD | 2012 | IP+OP | F+M | 50+ | All | 1, 2, 5 | 194 | a | 176 (91) | ||
| De Klerk [ | NLD | 2013 | IP+OP | F+M | 50+ | All | 541 | a | 499 (92) | |||
| Hegeman [ | NLD | 2004 | IP+OP | F+M | 50+ | All | 1, 5 | 156 | 116 (74) | a | 100 (86) | 64 |
| Wyers [ | NLD | 2014 | IP+OP | F+M | 50+ | All | 1, 2, 3 | 3057 | 1694 (55) | a | 1,359 (80) | 44 |
| Van Helden [ | NLD | 2008 | IP+OP | F+M | 50+ | All | 2, 8, 9 | 797 | 708 (89) | a | 568 (80) | 71 |
| Van Helden [ | NLD | 2007 | IP+OP | F+M | 50+ | All | 2, 5, 8, 9 | 425 | 288 (68) | a, b | 277 (96) | 65 |
| Langridge [ | GBR | 2007 | IP+OP | F+M | 50+ | All | 1 | c | 2,489 | |||
| Dumitrescu [ | NLD | 2008 | IP+OP | F+M | 50+ | All | 2, 8 | 1013 | 590 (58) | a, d | 100 (17) | 10 |
| Gallacher [ | GBR | 2007 | IP+OP | F+M | 50+ | All | 1 | a, e | 337 | |||
| Howat [ | GBR | 2007 | IP+OP | F+M | 50+ | All | 1 | e | 577 | |||
| Gallacher [ | GBR | 2005 | IP+OP | F+M | 50+ | All | 1 | d, e | 50 | |||
| Patient selection not conform recommendations ( | ||||||||||||
| Huntjens [ | NLD | 2013 | IP+OP | F+M | 50+ | NVF | 2, 9 | 834 | 834 (100) | |||
| Ahmed [ | IRL | 2012 | IP+OP | F+M | 45+ | All | 1 | 158 | 124 (78) | 124 (100) | 78 | |
| Abbad [ | FRA | 2016 | IP+OP | F+M | 75+ | All | 1 | 176 | 110 (64) | 110 (100) | 64 | |
| Premaor [ | GBR | 2010 | IP+OP | F | PM | All | 1 | 1641 | 1,641 (100) | |||
| Premaor [ | GBR | 2010 | IP+OP | F | PM | All | 1 | 1641 | f | 1,005 (61) | ||
| Dehamchia [ | FRA | 2014 | IP | F+M | No limit | All | 1, 5, 8, 9 | 872 | 338 (39) | g | 335 (99) | 38 |
| Nassar [ | FRA | 2014 | IP | F+M | 50+ | NVF | 1, 2, 5 | 528 | a | 362 (69) | ||
| Ganda [ | AUS | 2015 | NR | F+M | 45+ | All | 1, 2, 4, 10 | 828 | 560 (68) | b | 234 (42) | 28 |
| Beringer [ | GBR | 2006 | NR | F+M | No limit | All | 1 | a, h | 86 | |||
1: HET, 2: Pathological fracture, 3: Periprosthetic fracture, 4: Metabolic bone disorder, 5: Cognitive impairment, 6: Poor medical status/severe functional disability, 7: Patients who had osteoporosis screening in another hospital, 8: Already on osteoporosis treatment, 9: Patients residing outside the hospital’s postal area, 10: Nursing home or hostel residence
a a: All assessments completed, b: Follow-up data, c: Patients aged ≥65 years, d: Patients with osteoporosis, e: Patients with NVF, f; Patients aged <75 years, g: Pregnant women (n = 1), patients with primary hyperparathyroidism (n = 2), h Non-hip fracture patients
b Presented as % of FLS attenders
c Presented as % of patients selected for evaluation at the FLS
Fig. 1Percentage of studies reporting aspects of patient selection. * subjects as percentage of patients selected for evaluation at the FLS
Fig. 2Patients attending the FLS as percentage of patients selected for evaluation at the FLS, reported in 17 studies
Fig. 3Patients selected for publication (subjects) as percentage of patients selected for evaluation at the FLS, reported in 17 studies
Reported components of the FLS patients’ phenotype
| Author | Age (mean) | Men (%) | Fracture location (%) | BMI (mean) | ||
|---|---|---|---|---|---|---|
| Hip | Clinical VF | NV/NH | ||||
| IP+OP, F+M, 50+, all Fx | ||||||
| McLellan [ | ||||||
| Blonk [ | 64 | 24 | 9 | 5 | 86 | 27 |
| Eekman [ | 68 | 22 | ||||
| Fraser [ | 70 | 14 | 8 | 10 | 82 | |
| Malgo [ | 67 | 27 | 9 | 6 | 85 | |
| Naranjo [ | 71 | 23 | 22 | 6 | 72 | |
| Naranjo [ | 72 | 22 | 26 | |||
| Ojeda [ | 70 | 13 | 19 | 8 | 73 | 29 |
| Woltman [ | 73 | 21 | 23 | 2 | 75 | |
| Ong [ | 66 | 17 | ||||
| Van den Berg [ | 20 | |||||
| Huntjens [ | 67 | 23 | 6 | |||
| Bours [ | 23 | |||||
| De Klerk [ | 67 | 21 | 8 | 13 | 79 | 28 |
| De Klerk [ | 66 | 22 | ||||
| Hegeman [ | 67 | 26 | 11 | 3 | 86 | 25 |
| Wyers [ | 65 | 28 | 8 | 26 | ||
| Van Helden [ | 67 | 28 | 13 | 3 | 84 | |
| Range | 64–73 | 13–28 | 6–26 | 2–13 | 72–86 | 25–29 |
| IP+OP, F+M, 50+, NVF | ||||||
| Gallacher [ | 23 | 5 | Excl. | 95 | 24 | |
| Howat [ | 21 | 13 | Excl. | 87 | ||
| Huntjens [ | 67 | 27 | Excl. | |||
| Range | 67 | 21–27 | 5–13 | Excl. | 87–95 | 24 |
| IP+OP, F+M, all Fx, various ages | ||||||
| Langridge [ | 78 | 28 | ||||
| Ahmed [ | 19 | 2 | 3 | 95 | ||
| Abbad [ | 80 | 21 | 45 | |||
| Miscellaneous | ||||||
| Van Helden [ | 67 | 28 | ||||
| Dumitrescu [ | 68 | 27 | 17 | 4 | 79 | |
| Gallacher [ | 66 | 24 | 26 | Excl. | 74 | |
| Premaor [ | Excl. | 6 | <1 | 94 | 27 | |
| Premaor [ | Excl. | 10 | <1 | 90 | 27 | |
| Dehamchia [ | 67 | 25 | 28 | |||
| Nassar [ | 74 | 13 | 51 | Excl. | 49 | 24 |
| Ganda [ | 65 | 20 | ||||
| Beringer [ | 65 | 30 | Excl. | 41 | 59 | |
| Range overall | 64–80 | 13–30 | 2–51 | <1–41 | 49–95 | 24–29 |
Performance of assessments (DXA, VFA, laboratory tests, and fall risk assessment), and when reported, the results
| Author | DXA | Normal BMD (%) | Osteopenia (%) | Osteoporosis (%) | VFA | Any VF (%) | Grade 2/3 VF (%) | Lab | SECOB (%) | Vit. D def. (%) | Fall risk assessment | Fall risk (%) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| IP+OP, F+M, 50+, all Fx | ||||||||||||
| Blonk [ | + | 37 | + | + | – | |||||||
| Van den Berg [ | + | 12 | + | + | – | |||||||
| Hegeman [ | + | 23 | 44 | 33 | + | 22 | + | 69 | – | |||
| De Klerk [ | + | 35 | 38 | 27 | + | 42 | – | – | ||||
| Huntjens [ | + | 21 | 47 | 32 | – | + | + | |||||
| McLellan [ | + | – | + | – | ||||||||
| Eekman [ | + | – | + | – | ||||||||
| Fraser [ | + | 19 | 45 | 36 | – | + | – | |||||
| Malgo [ | + | 17 | 55 | 28 | – | + | 28 | 43 | – | |||
| Naranjo [ | + | 20 | 38 | 43 | – | + | – | |||||
| Naranjo [ | + | 13 | 44 | 42 | – | + | – | |||||
| Ojeda [ | + | – | + | – | ||||||||
| Bours [ | + | 15 | 46 | 30 | – | + | 27a, 70b | 64 | – | |||
| De Klerk [ | + | 30 | 49 | 21 | – | + | 3/11c | – | ||||
| Wyers [ | + | 23 | 48 | 30 | – | + | – | |||||
| Van Helden [ | + | 21 | 44 | 35 | – | – | + | 75 | ||||
| Woltman [ | + | 46 | – | – | – | |||||||
| Ong [ | + | – | – | – | ||||||||
| Range | 13–35 | 38–55 | 12–46 | 22–42 | 3–70 | 43–69 | 75–80 | |||||
| IP+OP, F+M, 50+, NVF | ||||||||||||
| Gallacher [ | + | 35 | 37 | 28 | + | 25 | 17 | + | – | |||
| Howat [ | + | + | 20 | – | + | |||||||
| Huntjens [ | + | – | – | + | 60 | |||||||
| Range | 35 | 37 | 28 | 20–25 | 17 | 60 | ||||||
| IP+OP, F+M, all Fx, various ages | ||||||||||||
| Abbad [ | + | 17 | 29 | 54 | + | 40 | – | + | ||||
| Langridge [ | + | – | + | + | ||||||||
| Ahmed [ | + | 33 | 38 | 29 | – | + | 64 | – | ||||
| Miscellaneous | ||||||||||||
| Dumitrescu [ | + | Excl. | Excl. | + | 57 | 31 | + | 50b | 62 | + | 79 | |
| Nassar [ | + | 52 | + | 37 | 21 | – | – | |||||
| Gallacher [ | + | Excl. | Excl. | – | + | 72 | – | |||||
| Dehamchia [ | + | 19 | 45 | 36 | – | + | – | |||||
| Beringer [ | + | – | + | 56 | – | |||||||
| Van Helden [ | + | 24 | 47 | 29 | – | – | + | 84 | ||||
| Premaor [ | + | 39 | 41 | 19 | – | – | – | |||||
| Premaor [ | + | 39 | 41 | 19 | – | – | – | |||||
| Ganda [ | + | – | – | – | ||||||||
| Range overall | 13–39 | 29–55 | 12–54 | 20–57 | 17–31 | 3–70 | 43–72 | 60–84 | ||||
Fig. 4Percentage of studies reporting assessments for fracture risk evaluation